全文获取类型
收费全文 | 1700606篇 |
免费 | 127009篇 |
国内免费 | 3826篇 |
专业分类
耳鼻咽喉 | 21943篇 |
儿科学 | 55774篇 |
妇产科学 | 46260篇 |
基础医学 | 242256篇 |
口腔科学 | 48986篇 |
临床医学 | 151475篇 |
内科学 | 335194篇 |
皮肤病学 | 38860篇 |
神经病学 | 132269篇 |
特种医学 | 64253篇 |
外国民族医学 | 242篇 |
外科学 | 258643篇 |
综合类 | 38947篇 |
现状与发展 | 4篇 |
一般理论 | 531篇 |
预防医学 | 124334篇 |
眼科学 | 40406篇 |
药学 | 124310篇 |
7篇 | |
中国医学 | 4504篇 |
肿瘤学 | 102243篇 |
出版年
2021年 | 12987篇 |
2019年 | 13671篇 |
2018年 | 20146篇 |
2017年 | 15366篇 |
2016年 | 16802篇 |
2015年 | 19157篇 |
2014年 | 26482篇 |
2013年 | 38310篇 |
2012年 | 53290篇 |
2011年 | 56062篇 |
2010年 | 33106篇 |
2009年 | 31006篇 |
2008年 | 52127篇 |
2007年 | 55428篇 |
2006年 | 55914篇 |
2005年 | 53235篇 |
2004年 | 51383篇 |
2003年 | 48763篇 |
2002年 | 46968篇 |
2001年 | 92155篇 |
2000年 | 93995篇 |
1999年 | 77307篇 |
1998年 | 19894篇 |
1997年 | 17430篇 |
1996年 | 17512篇 |
1995年 | 16843篇 |
1994年 | 15364篇 |
1993年 | 14154篇 |
1992年 | 57592篇 |
1991年 | 55487篇 |
1990年 | 53157篇 |
1989年 | 50923篇 |
1988年 | 46304篇 |
1987年 | 45072篇 |
1986年 | 42333篇 |
1985年 | 40112篇 |
1984年 | 29420篇 |
1983年 | 24943篇 |
1982年 | 13897篇 |
1979年 | 25540篇 |
1978年 | 17599篇 |
1977年 | 14899篇 |
1976年 | 13879篇 |
1975年 | 14547篇 |
1974年 | 17660篇 |
1973年 | 16952篇 |
1972年 | 15713篇 |
1971年 | 14487篇 |
1970年 | 13463篇 |
1969年 | 12557篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
21.
22.
23.
24.
25.
Widder Randolf A. Lappas Alexandra Rennings Corinna Hild Matthias Roessler Gernot F. Dietlein Thomas S. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(11):2581-2581
Graefe's Archive for Clinical and Experimental Ophthalmology - The published online version contains mistake as the author's first name and last name have been interchanged as "Hild... 相似文献
26.
Philip S. Vendittelli Bassent Botros Howard S. Rosman Viren Govindaraju Anwar Zaitoun Tariq S. Marroush 《The American journal of the medical sciences》2019,357(4):333-337
Coronary embolism (CE) is an uncommon and unique cause of acute myocardial infarction. In this report, we review 216 cases of CE including 2 new cases from our institution. The mean patient age was 52.5 years and 62% of the patients were males. Chest pain was the most common presenting symptom followed by dyspnea, and the most commonly affected vessel was the left anterior descending artery. Leading etiologies of the embolus were atrial fibrillation, septic emboli, and iatrogenic causes. Treatment approaches varied with thrombus aspiration being used in 30% of cases. In-hospital mortality rate was 36% and 13% of the cases were complicated by cerebrovascular accident. CE is a unique pathology that leads to acute myocardial infarction. It portends a high mortality rate and requires a high level of suspicion as symptoms may be misleading. Further research is needed in order to improve recognition and management and to lower associated mortality. 相似文献
27.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
28.
Krishna S. Iyer 《Platelets》2020,31(4):474-482
Abstract Platelets are small, anucleated effector cells that play an important role in linking the hemostatic and inflammatory processes in the body. Platelet function is known to be altered under various inflammatory conditions including aging. A gain in platelet function during aging can increase the risk of thrombotic events, such as stroke and acute myocardial infarction. Anti-platelet therapy is designed to reduce risk of serious cerebrovascular and cardiovascular events, but the adverse consequences of therapy, such as risk for bleeding increases with aging as well. Age-associated comorbidities such as obesity, diabetes, and hyperlipidemia also contribute to increased platelet activity and thus can enhance the risk of thrombosis. Therefore, identification of unique mechanisms of platelet dysfunction in aging and in age-associated comorbidities is warranted to design novel antiplatelet drugs. This review outlines some of the current areas of research on aging-related mechanisms of platelet hyperactivity and addresses the clinical urgency for designing anti-platelet therapies toward novel molecular targets in the aging population. 相似文献
29.
30.